Literature DB >> 19779798

Progressive necrotic encephalopathy following tacrolimus therapy for liver transplantation.

Paolo Aridon1, Paolo Ragonese, Norma Di Benedetto, Giovanni Grasso, Pier Giulio Conaldi, Marco D'Amelio, Giovanni Savettieri.   

Abstract

Previously described neurologic damage induced by immunosuppressive treatments includes transient or reversible central nervous system involvement. We describe a 57-year-old man who underwent liver transplantation and was started on immunosuppressive therapy with tacrolimus (FK506). Six months later, he started complaining of a progressive motor and sensory impairment of the left side, together with cognitive impairment. Brain MRI showed an enlarging lesion of the white matter with peripheral contrast enhancement. PET study indicated severe hypometabolism in the right hemisphere and spectroscopic MRI showed a peak of choline and relative reduction of other metabolites. Findings of CSF examinations and cultures, serology, and molecular techniques were normal. Tacrolimus treatment was stopped. A cerebral biopsy of the lesion showed a sub acute necrotizing process. In the following months, cognitive status of the patient tended to improve although he remained hemiplegic, while serial MRI confirmed the tendency to the recovery of the lesion that was still present 1 year after. The present observation describes a progressive encephalopathy associated with immune suppression with an unusual feature and permanent brain damage.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19779798     DOI: 10.1007/s10072-009-0149-0

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  7 in total

Review 1.  Immunosuppressive-associated leukoencephalopathy in organ transplant recipients.

Authors:  N Singh; A Bonham; M Fukui
Journal:  Transplantation       Date:  2000-02-27       Impact factor: 4.939

2.  Characteristics and antecedents of progressive multifocal leukoencephalopathy in an insured population.

Authors:  P M Eng; B R Turnbull; S F Cook; J E Davidson; T Kurth; J D Seeger
Journal:  Neurology       Date:  2006-09-12       Impact factor: 9.910

Review 3.  Posterior reversible encephalopathy syndrome in childhood with hematologic/oncologic diseases.

Authors:  Sung Chul Won; Seung Yeon Kwon; Jung Woo Han; Seong Yeol Choi; Chuhl Joo Lyu
Journal:  J Pediatr Hematol Oncol       Date:  2009-07       Impact factor: 1.289

4.  A reversible posterior leukoencephalopathy syndrome.

Authors:  J Hinchey; C Chaves; B Appignani; J Breen; L Pao; A Wang; M S Pessin; C Lamy; J L Mas; L R Caplan
Journal:  N Engl J Med       Date:  1996-02-22       Impact factor: 91.245

5.  FK506-induced neurotoxicity in liver transplantation.

Authors:  E F Wijdicks; R H Wiesner; L J Dahlke; R A Krom
Journal:  Ann Neurol       Date:  1994-04       Impact factor: 10.422

6.  FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. Multicenter Trial.

Authors:  S V McDiarmid; R W Busuttil; N L Ascher; J Burdick; A M D'Alessandro; C Esquivel; M Kalayoglu; A S Klein; J W Marsh; C M Miller
Journal:  Transplantation       Date:  1995-02-27       Impact factor: 4.939

7.  Severe tacrolimus leukoencephalopathy after liver transplantation.

Authors:  Janneke Schuuring; Pieter Wesseling; Aad Verrips
Journal:  AJNR Am J Neuroradiol       Date:  2003 Nov-Dec       Impact factor: 3.825

  7 in total
  2 in total

1.  Intravascular large B-cell lymphoma affecting multiple cranial nerves: A histopathological study.

Authors:  Andrea Porzionato; Guido Pelletti; Luisa Barzon; Martina Contran; Aron Emmi; Angelo Arminio; Veronica Macchi; Raffaele De Caro
Journal:  Neuropathology       Date:  2021-09-19       Impact factor: 2.076

2.  Four cases of progressive multifocal leukoencephalopathy in iatrogenic immunocompromised patients.

Authors:  Alessia Bianchi; Paolo Ragonese; Maria Aurelia Banco; Sabrina Realmuto; Giulia Vazzoler; Erika Portera; Giuseppe La Tona; Giuseppe Salemi
Journal:  eNeurologicalSci       Date:  2020-05-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.